,i #aaeth ,,congress #ast ,session ,h4 ,r4 #bjbe ,,in ,,the ,,house ,,of ,,representatives ,april #f1 #bjag ,mr4 ,griffith 7for himself and ,mr4 ,costello of ,pennsylvania7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend section #eje7;c77#c77;,e7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act to prevent certain applications from being considered ineligible for approval under section #eje7;c7 of such ,act on the basis that the proposed labeling includes information describing abuse-deterrent properties that otherwise would be blocked by exclusivity under clause 7iii7 or 7iv7 of section #ejc7;c77#c77;,e7 of such ,act1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,abuse-,deterrent ,opioids ,plan for ,tomorrow ,act of #bjag4 #b4 ,labeling information describing abuse-deterrent properties 7a7 ,in general ,subparagraph 7,e7 of section #eje7;c77#c7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;c77#c77 is amended by adding at the end the following new clause3 7vi7 ,a drug for which an application 7or a supplement to an application7 described in subsection 7b77#b7 is submitted shall not be considered ineligible for approval under this subsection on the basis that its labeling includes information describing the abuse-deterrent properties of the drug 7including abuse-deterrent claims7 that otherwise would be blocked by exclusivity under clause 7iii7 or 7iv7 of this subparagraph if-- 7,i7 the investigation or investigations relied upon by the applicant for approval of the labeling information were conducted by or for the applicant or the applicant has obtained a right of reference or use from the person by or for whom the investigation or investigations were conducted2 and 7,,ii7 the drug has meaningful technological differences compared to the drug otherwise protected by exclusivity under clause 7iii7 or 7iv7 of this subparagraph4 4 7b7 ,guidance ,the ,secretary of ,health and ,human ,services shall-- 7#a7 not later than #ah months after the date of enactment of this ,act1 issue draft guidance regarding the award and scope of exclusivity under clauses 7iii7 and 7iv7 of section #eje7;c77#c77;,e7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;c77#c77;,e77 for drugs with properties designed to deter abuse and the exception to such exclusivity described in clause 7vi7 of such section #eje7;c77#c77;,e71 as added by subsection 7a72 and 7#b7 not later than #ah months after the close of the period for receiving public comments on such draft guidance1 publish final guidance on the topics described in paragraph 7#a74 7c7 ,effective date ,the amendment made by subsection 7a7 applies with respect to applications1 and supplements to applications1 that are submitted or pending under section #eje7;b7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7;b77 on or after ,january #a1 #bjag4